By the end of 2027, a new 3000m2 facility on the grounds of the current Carrigtwohill site would allow for 25 million more patient doses of contrast media annually, contributing to the expanding demand worldwide.

Micheál Martin, an Taoiseach, turned the sod at the location. "GE HealthCare has been manufacturing in Ireland for more than 30 years, and has invested extensively in the Carrigtwohill site and the people working here," added Martin.

"I am delighted to welcome this significant new investment here in Cork, which is testament to the commitment of GE HealthCare in Ireland, and also to our highly skilled workforce," he added.



Injectable diagnostic imaging chemicals called contrast media are used in medical imaging to improve the visibility of organs, blood vessels, and tissues.

Ageing populations and the rising incidence of chronic illnesses worldwide are predicted to double the demand for iodine-based contrast media, which are used in X-ray, CT, and interventional treatments, during the course of the next ten years.

President & CEO of GE Healthcare's Pharmaceutical Diagnostics segment, Kevin O’Neill, told Morning Ireland that Cork is an excellent location because of the "fantastic team" and "great access to global markets".

He said Carrigtwohill was the right place for the investment, and it wasn't in doubt even after the election of US President Donald Trump.

Mr O'Neill also said GE Healthcare will adapt if President Trump introduces tariffs.